McKesson outlines fiscal 2027 adjusted EPS of $44.20 to $45.00 while planning $5B in share repurchases (NYSE:MCK)
McKesson (MCK) Q1 FY2027 earnings call: raised EPS guide to $44.20â$45.00, strong revenue, GLP-1 trends, Wellverse spinoffâread now.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
McKesson (MCK) Q1 FY2027 earnings call: raised EPS guide to $44.20â$45.00, strong revenue, GLP-1 trends, Wellverse spinoffâread now.
McKesson outlines fiscal 2027 adjusted EPS of $44.20 to $45.00 while planning $5B in share repurchases (NYSE:MCK) | Seeking Alpha
Earnings Call Insights: McKesson (MCK) Q1 fiscal 2027
Management View
CEO & Chairman Brian Tyler said the quarter showed âbroad-based momentum across the enterpriseâ as âRevenues increased 8% to $105 billion and adjusted earnings per diluted share increased 20% to $9.93,â and added that the performance âgives us the confidence to
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
Why did McKesson raise its fiscal 2027 EPS outlook?
McKesson raised its fiscal 2027 EPS outlook due to strong Q1 performance, broad-based momentum, and confidence in ongoing operational execution.
What are the main risks facing McKesson currently?
Main risks include lower branded pharmaceutical pricing, branded to generic conversions, uncertain policy impacts (e.g. 340B), and separation-related financing effects.
How is the Medical-Surgical Solutions separation impacting McKesson?
The separation led to the Apollo minority investment, new stand-alone debt financing, establishing the business as Wellverse starting January 2027, and related accounting adjustments and interest expenses.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Starwood Capital teams up with Trez Capital on U.S. residential land financing
Starwood Capital and Trez Capital partner on U.S. housing development loans, targeting $1B annually.
Athene Holding Ltd. 7.75%DP RT PFD E declares $0.4844 dividend (NYSE:ATH.PR.E)
Athene Holding declares a $0.4844 quarterly dividend with a 7.95% forward yield.
Solana Company Stakes 500K SOL on Tokyo Cluster, Validator Rewards Expected by Q3 2026
A Solana infrastructure firm has pledged 500,000 SOL to support its Tokyo cluster, with first validator rewards projected for Q3 2026, signaling confidence in network decentralization and Asian expansion.
Barfresh outlines $23M-$26M FY2026 revenue outlook while targeting partial commissioning of Defiance plant by end of 2026 (NASDAQ:BRFH)
Barfresh (BRFH) Q2 2026 earnings call recap: Arps-driven revenue growth, production ramp issues, and revised FY2026 guidance.